NEWS
November 24, 2022.
November 21, 2022.
November 14, 2022.
November 11, 2022.
April 21, 2022
March 27, 2022
February 23, 2022
February 22, 2022
February 3, 2022
November 26, 2021
SelectImmune Pharma holds digital investor meeting
November 18, 2021
Quarterly Report 1, 2021/2022
September 17, 2021
SelectImmune Pharma holds digital investor meeting
August 31, 2021
Year-end Report 2020/2021
August 13, 2021
SelectImmune Pharma will implement reporting in English
December 18, 2020
Therapeutic proteins from nice bacteria combat infection
September 16, 2020
SelectImmune Pharma announces new patent granted for IRF7 inhibitors case
June 16, 2020
Ann Gidner to become new CEO of SelectImmune Pharma
April 27, 2020
SelectImmune Pharma appoints new CEO
November 21, 2019
Bulletin from the AGM of SelectImmune Pharma AB
August 30, 2019
New member of the Board of Directors
August 29, 2019
SelectImmune Pharma AB: Year-end Report 2018/2019
July 9, 2019
Trading of subscription warrants commences
June 14, 2019
Heavily oversubscribed new issue in SelectImmune Pharma
2022-02-23
Delårsrapport 2 Räkenskapsåret 2021/2022
2021-11-18
Delårsrapport 1 Räkenskapsåret 2021/2022
2021-08-31
Bokslutskommuniké Räkenskapsåret 2020/2021
2021-05-25
Delårsrapport 3 Räkenskapsåret 2020/2021
2020-06-16
Ann Gidner blir ny VD i SelectImmune Pharma
2020-04-23
SelectImmune Pharma byter VD
2019-08-30
Ny styrelseledamot
2019-07-09
Nu inleds handeln med teckningsoptioner
Immunotherapy – A Complement to Antibiotics
April 21, 2022. Film about SelectImmune Pharma’s drug development program and the scientific discoveries that have defined new and exciting tools for treating infections.
Swedish language version.
SelectImmune Pharma digitalt investerarmöte 7 december 2021
Uppföljning av bolagsstämma med presentation och frågestund
